Skip to content
Friday 21 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,771.14
+0.21%
DAX
26,062.77
+0.31%
CAC 40
8,468.34
+0.18%
STOXX 50
6,448.19
+0.41%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Sunday 09 February 2020 2:58 pm  |  Updated:  Sunday 09 February 2020 5:54 pm

Fresh blow for Woodford investors as biotech sell-off fails

By: Anna Menin

Add as a preferred source on Google
neil woodford
Administrators are in the process of selling off assets from Woodford's fund

Investors in the failed flagship fund of Neil Woodford are facing a further blow after a £550m deal to rescue a portfolio of his stakes in biotech startups collapsed, raising concerns the holdings will be offloaded in a fire sale. 

WG Partners, a boutique investment bank specialising in life sciences, had been trying to assemble a group of international investors to save most of the fund’s illiquid holdings, but has now missed the deadline to complete the deal, according to the Sunday Times.

Administrator Link is overseeing the liquidation of the Equity Income Fund’s holdings after deciding to wind it up last October. The fund had been frozen since June, leaving hundreds of thousands of investors trapped, after becoming overwhelmed by withdrawal requests. 

The suspension sparked the investment industry’s biggest scandal in decades, and led Woodford to shutter his investment company shortly after Link announced the fund’s closure.

Equity Income investors received their first payout, worth between 48p and 58p on the pound, late last month following the sale of the fund’s liquid assets by Blackrock. These liquid holdings made up 74 per cent of the total portfolio.

Park Hill is still in the process of finding buyers for its illiquid — and thus harder-to-sell — holdings. These include stakes in small biotech firms, including drug developer Immunocore and gene-sequencing firm Oxford Nanopore. 

In November, Park Hill gave WG Partners a period of exclusivity to assemble a group of investors to purchase the biotech portfolio, which accounts for most of the 26 per cent of remaining assets, but the deal has now fallen apart, the Sunday Times reported. 

Link declined to comment on the deal falling through, but a spokesperson said: “It is in the best interests of all investors for the fund to be wound up on the basis of an ‘orderly realisation’ of the fund’s assets, which involves the sale of the fund’s assets over a reasonable period of time.”

WG Partners declined to comment on the reports.

Read more

Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

Hikma produces generic drugs

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Jobs and Money

Categories

  • Investing

Related Topics

  • Neil Woodford

Trending Articles

  • House prices in wealthy London boroughs fall by up to £300,000

  • As it happened: Miners fuel FTSE 100 recovery; oil jumps as Trump claims Strait of Hormuz

  • City law firm sues prominent Emirati business family

  • Amanda Blanc has worked her magic at Aviva

  • As it happened: FTSE 100 rallies after JD Sports drags on blue chips; oil jumps again

More from Morning Wire

  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
  • The former African gold miner taking on the billionaire Issa brothers

    Markets
    Screenshot showing July 2026 news article layout with no specific categories or tags on a general news/business website
  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
  • Arm Holdings plc Reports Results for the First Quarter of the Fiscal Year Ending 2027

    Business Wire
  • FTSE 100 firm agrees £5.7bn takeover in latest private equity swoop

    Markets
    GettyImages 2211256637 showing a significant event or figure relevant to recent news updates in the business sector
  • Thames Water faces fresh threat to survival after pensions regulation breach

    Water
    Thames Water infrastructure with pipes and maintenance workers, highlighting water management efforts in London
  • Astrazeneca explores $400bn megadeal with US rival 

    Markets
    AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.
  • CI Financial Holdings Ltd. Prices Private Offering of U.S. Dollar Junior Subordinated Notes

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook